Duke Cancer Institute

This week, we're focusing on prostate cancer and examining how treatment is becoming more personalised.

We talk with Anis Hamid of Memorial Sloan Kettering Cancer Centre, Daniel Keizman of Ishilov Sorosky Medical Centre, Susan Halabi of Duke Cancer Institute and Andrew Armstrong of Duke University Medical Centre to hear how circulating tumour DNA assays and prognostic models are shaping personalised treatment of prostate cancer.

First, Anis Hamid discusses results of a correlative study of the EMSIMET trial investigating germline genetic correlates which could predict benefit of intensified therapy in metastatic hormone-sensitive prostate cancer treated with androgen deprivation therapy plus non-steroidal anti-androgen or enzalutamide.

So Enzomet was a pivotal phase three randomized multicenter international clinical trial that randomized patients with metastatic androgen pathway modulation sensitive cross-A cancer to a control arm of testosterone suppression plus a non-steroidal anti-androgen versus the same testosterone suppression plus enzalutamide, the novel androgen receptor inhibitor.

And I'll give you just like a little inside scoop.

We just purchased three properties in Durham right next to Duke Cancer Institute.

Oh, my

gosh.

That's kind of like up in the air iffy right now, but I'm pretty sure it'll all line up perfectly.

And, you know, like, for example, the Michael Strahan's of the world, right? His daughter is ill with brain cancer.

Where do you go? The best place available, Duke Cancer Institute, because it's the designated brain cancer center.

Most people don't have that opportunity.

In today's episode, we spoke with Angeles Alvarez-Sicord, MD, MHSC.

Dr. Sicord is a professor of obstetrics and gynecology and a member of Duke Cancer Institute in Durham, North Carolina.

In our exclusive interview, Dr. Sicord discussed the emergence of B7H4 as an attractive antibody drug conjugate target in gynecologic cancers, noting that expression rates of 80% to 90% or higher across endometrial and ovarian cancers distinguish it favorably from other targets such as folate receptor alpha and HER2, where high expression thresholds are often required for meaningful benefit.

She also highlighted a mechanistic distinction.

At the two thousand and twenty-six Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Westin from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo from the European Institute of Oncology IRCCS in Milan, Italy, Dr. Alexander Olawuyi from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Gottfried Koneczny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of pre-recorded video case presentations by Professor Jonathan Lederman from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matulonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient of Dr. Matulonis, a fifty-five-year-old woman with a BRCA1-mutated ovarian cancer with disease progression after platinum doublets and PARP inhibitors, but with an elevated folate receptor alpha level.

She started mirvetuximab at six milligrams per kilo IV, and after two cycles had a very nice decrease in her cancer burden with decrease in the size of multiple peritoneal implants, but did have grade two eye toxicity.

At the two thousand and twenty-six Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Weston from the MD Anderson Cancer Center in Houston, and faculty members Professor Nicoletta Colombo from the European Institute of Oncology IRCCS in Milan, Italy, Dr. Alexander Olawuyi from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Gottfried Koneczny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of pre-recorded video case presentations by Professor Jonathan Lederman from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matulonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient of Dr. Matulonis, a fifty-five-year-old woman with a BRCA1 mutated ovarian cancer with disease progression after platinum doublets and PARP inhibitors, but with an elevated folate receptor alpha level.

She started mirvetuximab at six milligrams per kilo IV, and after two cycles had a very nice decrease in her cancer burden, with decrease in the size of multiple peritoneal implants, but did have grade two eye toxicity.

At the two thousand and twenty-six Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Westin from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo from the European Institute of Oncology IRCCS in Milan, Italy, Dr. Alexander Olawuyi from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Gottfried Koneczny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of pre-recorded video case presentations by Professor Jonathan Ledermann from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matulonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient from Professor Ledermann, a fifty-two-year-old woman who presented in two thousand and twenty with ascites and a pleural effusion, a complex ovarian mass, and omental thickening on CT.

She was also found to have a germline BRCA1 mutation and was treated with neoadjuvant carboplatin, paclitaxel, and bevacizumab.

At the two thousand and twenty-six Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Westin from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo from the European Institute of Oncology IRCCS in Milan, Italy, Dr. Alexander Olawuyi from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Gottfried Koneczny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of pre-recorded video case presentations by Professor Jonathan Ledermann from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matulonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient from Professor Ledermann, a fifty-two-year-old woman who presented in two thousand and twenty with ascites and a pleural effusion, a complex ovarian mass, and omental thickening on CT.

She was also found to have a germline BRCA1 mutation and was treated with neoadjuvant carboplatin, paclitaxel, and bevacizumab.